Mobile

A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients three to six months after allogeneic hematopoietic cell transplantat...

Update Il y a 4 ans
Reference: EUCTR2006-003970-89

A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients three to six months after allogeneic hematopoietic cell transplantation in whom iron overload is present

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of this study is to evaluate if ICL670 can provide clinically acceptable chelation, as measured by serum ferritin to patients presenting with iron overload three to six months after related or unrelated HCT (serum ferritin levels of ≥ 1000 ng/ml) irrespective of conditioning regimen.

Inclusion criteria

  • allogeneic hematopoietic cell transplantation with iron overload

Links